ConvaTec Group’s (CTEC) “Outperform” Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their outperform rating on shares of ConvaTec Group (LON:CTEC) in a research note published on Monday morning, Marketbeat reports. Royal Bank Of Canada currently has a GBX 315 target price on the stock.

CTEC has been the subject of a number of other reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 315 price target on shares of ConvaTec Group in a research note on Wednesday, April 8th. Citigroup reduced their price objective on shares of ConvaTec Group from GBX 250 to GBX 230 and set a “neutral” rating on the stock in a research note on Monday, May 18th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 300 target price on shares of ConvaTec Group in a report on Monday, June 8th. JPMorgan Chase & Co. dropped their target price on shares of ConvaTec Group from GBX 307 to GBX 294 and set an “overweight” rating for the company in a research report on Friday, May 22nd. Finally, UBS Group reissued a “buy” rating and issued a GBX 375 price target on shares of ConvaTec Group in a research note on Monday, May 18th. Eight research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of GBX 306.

ConvaTec Group Stock Performance

ConvaTec Group stock opened at GBX 225.40 on Monday. The company has a current ratio of 1.93, a quick ratio of 0.96 and a debt-to-equity ratio of 121.83. ConvaTec Group has a 1 year low of GBX 193 and a 1 year high of GBX 259.30. The company has a market cap of £4.41 billion, a PE ratio of 26.21, a PEG ratio of 0.93 and a beta of 0.77. The company’s 50-day moving average is GBX 212.21 and its two-hundred day moving average is GBX 221.

Insider Activity at ConvaTec Group

In other news, insider Jonny Mason purchased 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were acquired at an average cost of GBX 201 per share, for a total transaction of £100,500. 0.98% of the stock is currently owned by company insiders.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.